| Autor: |
Abdul‐Rahman, Toufik, Awuah, Wireko Andrew, Mikhailova, Tatiana, Kalmanovich, Jacob, Mehta, Aashna, Ng, Jyi Cheng, Coghlan, Megan Ariel, Zivcevska, Marija, Tedeschi, Alexander J., de Oliveira, Emerson Costa, Kumar, Akinchita, Cantu‐Herrera, Emiliano, Lyndin, Mykola, Sikora, Kateryna, Alexiou, Athanasios, Bilgrami, Anwar L., Al‐Ghamdi, Khalid Mohammed, Perveen, Asma, Papadakis, Marios, Ashraf, Ghulam Md |
| Předmět: |
|
| Zdroj: |
Biofactors; Jul2024, Vol. 50 Issue 4, p693-708, 16p |
| Abstrakt: |
Alzheimer's disease (AD) constitutes a multifactorial neurodegenerative pathology characterized by cognitive deterioration, personality alterations, and behavioral shifts. The ongoing brain impairment process poses significant challenges for therapeutic interventions due to activating multiple neurotoxic pathways. Current pharmacological interventions have shown limited efficacy and are associated with significant side effects. Approaches focusing on the early interference with disease pathways, before activation of broad neurotoxic processes, could be promising to slow down symptomatic progression of the disease. Curcumin—an integral component of traditional medicine in numerous cultures worldwide—has garnered interest as a promising AD treatment. Current research indicates that curcumin may exhibit therapeutic potential in neurodegenerative pathologies, attributed to its potent anti‐inflammatory and antioxidant properties. Additionally, curcumin and its derivatives have demonstrated an ability to modulate cellular pathways via epigenetic mechanisms. This article aims to raise awareness of the neuroprotective properties of curcuminoids that could provide therapeutic benefits in AD. The paper provides a comprehensive overview of the neuroprotective efficacy of curcumin against signaling pathways that could be involved in AD and summarizes recent evidence of the biological efficiency of curcumins in vivo. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text